ContraFect (CFRX) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last twelve months. There are currently 2 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CFRX shares.
View CFRX analyst ratings or view top-rated stocks.

4 analysts have issued twelve-month price targets for ContraFect's shares. Their CFRX share price forecasts range from $3.00 to $560.00. On average, they expect the company's stock price to reach $180.75 in the next year. This suggests a possible upside of 13,593.2% from the stock's current price.
View analysts price targets for CFRX or view top-rated stocks among Wall Street analysts.

ContraFect's stock was trading at $7.68 at the start of the year. Since then, CFRX stock has decreased by 82.8% and is now trading at $1.32.
View the best growth stocks for 2023 here.

ContraFect saw a increase in short interest in May. As of May 15th, there was short interest totaling 166,000 shares, an increase of 140.9% from the April 30th total of 68,900 shares. Based on an average daily volume of 3,970,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 4.6% of the company's stock are sold short.
View ContraFect's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our CFRX earnings forecast.

ContraFect Co. (NASDAQ:CFRX) announced its earnings results on Friday, March, 31st. The biotechnology company reported ($16.14) earnings per share (EPS) for the quarter.

ContraFect's stock reverse split before market open on Tuesday, February 14th 2023. The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX).

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

ContraFect's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (5.49%), Acadian Asset Management LLC (3.26%), State Street Corp (1.74%), Virtu Financial LLC (0.86%), Simplex Trading LLC (0.00%) and FNY Investment Advisers LLC (0.00%).
View institutional ownership trends.

Shares of CFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CFRX stock can currently be purchased for approximately $1.32.

ContraFect (NASDAQ:CFRX) has a market capitalization of $2.07 million. The biotechnology company earns $-65,150,000.00 in net income (profit) each year or ($88.03) on an earnings per share basis.

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The official website for the company is www.contrafect.com. The biotechnology company can be reached via phone at (914) 207-2300 or via email at mmessinger@contrafect.com.